Tag Archives: Oren Livnat

Aerie Pharma (AERI) Gets a Buy Rating from H.C. Wainwright

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $57. The company’s shares closed yesterday at $21.49, close to its 52-week low of

H.C. Wainwright Maintains Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

H.C. Wainwright analyst Oren Livnat maintained a Hold rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $147. The company’s shares closed yesterday at $136.68. Livnat said: “Our $147 12-month target (from $153) is

H.C. Wainwright Thinks Aerie Pharma’s Stock is Going to Recover

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $57. The company’s shares closed yesterday at $21.96, close to its 52-week low of $21.78. Livnat said:

Cara Therapeutics (CARA) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a price target of $28. The company’s shares opened today at $20.45. Livnat observed: “Our $28 price target (from $26) is

H.C. Wainwright Keeps a Buy Rating on Taiwan Liposome Company Ltd (TLC)

In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on Taiwan Liposome Company Ltd (TLC – Research Report), with a price target of $10. The company’s shares closed on Friday at $5.31, close to its

Lipocine (LPCN) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Lipocine (LPCN – Research Report) today and set a price target of $5. The company’s shares closed yesterday at $1.93. Livnat noted: “Valuation and risk. Our $5 target includes $3/share